bupropion sustained-release / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 27 Diseases   22 Trials   22 Trials   341 News 


«1234567»
  • ||||||||||  Chantix (varenicline) / Pfizer
    Biomarker, Trial completion, Trial completion date, Trial primary completion date:  Pharmacogenetics, Emotional Reactivity and Smoking (clinicaltrials.gov) -  Dec 23, 2019   
    P2/3,  N=646, Completed, 
    Phase classification: P=N/A --> P4 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Dec 2019 | Trial primary completion date: Dec 2020 --> Dec 2019
  • ||||||||||  Chantix (varenicline) / Pfizer
    Biomarker, Trial primary completion date:  Pharmacogenetics, Emotional Reactivity and Smoking (clinicaltrials.gov) -  Dec 20, 2019   
    P2/3,  N=646, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Dec 2019 | Trial primary completion date: Dec 2020 --> Dec 2019 Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  bupropion sustained-release / generics
    Journal:  Drugs for smoking cessation. (Pubmed Central) -  Nov 18, 2019   
    The proportion of smokers who use smoking cessation medications who benefit from doing so decreases during the course of the first year, but a net benefit still remains at 12 months. No abstract available
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Enrollment open:  CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) -  Nov 14, 2019   
    P4,  N=120, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion date, Trial primary completion date:  Combining Varenicline and Bupropion for Smoking Cessation (clinicaltrials.gov) -  Sep 3, 2019   
    P3,  N=385, Active, not recruiting, 
    It allows for the monitoring of thoughts and feelings associated with increased suicidal risk as well as levels of thoughts about suicide. Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2019 --> May 2020
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking (clinicaltrials.gov) -  Aug 19, 2019   
    P=N/A,  N=45, Active, not recruiting, 
    Its curative effect is close to that of bupropion hydrochloride sustained-release tablets, and it has good clinical compliance and less adverse reactions. Recruiting --> Active, not recruiting | N=10 --> 45 | Trial completion date: Feb 2021 --> Feb 2020 | Trial primary completion date: Nov 2020 --> Feb 2020
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Enrollment open:  PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) -  Aug 1, 2019   
    P4,  N=60, Recruiting, 
    However, α4β2* receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males. Not yet recruiting --> Recruiting
  • ||||||||||  methamphetamine / Generic mfg.
    Trial completion, Enrollment change:  Bupropion in the Treatment of Methamphetamine Dependence (clinicaltrials.gov) -  Jul 25, 2019   
    P=N/A,  N=40, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=60 --> 40
  • ||||||||||  Chantix (varenicline) / Pfizer
    Enrollment closed, Enrollment change:  Treating Smokeless Tobacco Use in Rural Veterans (clinicaltrials.gov) -  Jul 24, 2019   
    P=N/A,  N=123, Active, not recruiting, 
    Recruiting --> Completed | N=60 --> 40 Enrolling by invitation --> Active, not recruiting | N=50 --> 123
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects (clinicaltrials.gov) -  Jul 23, 2019   
    P4,  N=73, Completed, 
    Enrolling by invitation --> Active, not recruiting | N=50 --> 123 Recruiting --> Completed | N=126 --> 73 | Trial completion date: Oct 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Enrollment change:  Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) -  Jul 22, 2019   
    P=N/A,  N=165, Active, not recruiting, 
    Recruiting --> Completed | N=126 --> 73 | Trial completion date: Oct 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019 Recruiting --> Active, not recruiting | N=400 --> 165
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) -  Jul 11, 2019   
    P=N/A,  N=400, Recruiting, 
    Recruiting --> Active, not recruiting | N=400 --> 165 Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Jun 12, 2019   
    P2,  N=58, Completed, 
    Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 Active, not recruiting --> Completed
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion date:  Combining Varenicline and Bupropion for Smoking Cessation (clinicaltrials.gov) -  May 14, 2019   
    P3,  N=385, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: May 2019 --> May 2020
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Enrollment closed:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  May 13, 2019   
    P2,  N=60, Active, not recruiting, 
    Trial completion date: May 2019 --> May 2020 Recruiting --> Active, not recruiting
  • ||||||||||  Chantix (varenicline) / Pfizer
    Enrollment open:  Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) -  May 6, 2019   
    P3,  N=392, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Chantix (varenicline) / Pfizer, NN1213 / Novo Nordisk
    Trial completion:  Web-based Smoking Cessation Program for Tribal College Students (clinicaltrials.gov) -  Apr 19, 2019   
    P3,  N=251, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion date, Trial primary completion date:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Jan 14, 2019   
    P2,  N=60, Recruiting, 
    Initiation date: Jan 2019 --> Aug 2019 Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
  • ||||||||||  Chantix (varenicline) / Pfizer, NN1213 / Novo Nordisk
    Enrollment closed, Trial primary completion date:  Web-based Smoking Cessation Program for Tribal College Students (clinicaltrials.gov) -  Oct 12, 2018   
    P3,  N=300, Active, not recruiting, 
    These findings indicate the important roles of varenicline in negative affect processing and negative emotional reactivity in the course of smoking cessation. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Mar 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers (clinicaltrials.gov) -  Oct 11, 2018   
    P4,  N=133, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Mar 2019 Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Smoking Cessation for People Living With HIV/AIDS (clinicaltrials.gov) -  Oct 4, 2018   
    P=N/A,  N=400, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Trial completion, Phase classification, Enrollment change:  Combined Pharmaco/Behavior Therapy in Adolescent Smokers (clinicaltrials.gov) -  Oct 2, 2018   
    P2,  N=134, Completed, 
    Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Completed | Phase classification: PN/A --> P2 | N=216 --> 134
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Journal:  Step Care treatment for smoking cessation. (Pubmed Central) -  Jul 18, 2018   
    Recruiting --> Completed | Phase classification: PN/A --> P2 | N=216 --> 134 For smokers not achieving tobacco abstinence 6 months after randomization with Step 1, the intensity of the intervention increased to four counseling sessions, bupropion sustained-release, nine telephone calls and three mailings (Step 2)...No abstract available
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Bupropion for Depression in ESRD Patients on Hemodialysis (clinicaltrials.gov) -  Jul 17, 2018   
    P4,  N=1, Terminated, 
    For smokers not achieving tobacco abstinence 6 months after randomization with Step 1, the intensity of the intervention increased to four counseling sessions, bupropion sustained-release, nine telephone calls and three mailings (Step 2)...No abstract available N=40 --> 1 | Trial completion date: Dec 2018 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; Study stopped due to difficulty recruiting